Core Viewpoint - Norwegian police have fined Equinor for pollution at its Mongstad refinery, indicating regulatory scrutiny on environmental practices in the oil and gas sector [1] Company Summary - Equinor, a Norwegian oil and gas company, has faced penalties due to pollution issues at its Mongstad refinery located on Norway's west coast [1]

Prediction markets are emerging as one of fintech's fastest-growing revenue streams, according to new analysis from Citizens Financial Group, cited in a Bloomberg report. Platforms that allow users to... ...

As McKinsey & Co. partners gathered in the consulting giant’s birthplace in late October, Bob Sternfels delivered a rallying cry. “We will kick some ass as we start our second century,” the firm’s top executive told the thousands of attendees.But away from the 100-year festivities in Chicago, McKinsey bosses have been conveying a more pragmatic message: It’s time to get leaner. The firm’s leadership has discussed with managers in non-client-facing departments the need to cut about 10% of headcount across th ...

Shares have tumbled in Asia and U.S. futures also fell ahead of the release of U.S. employment and inflation reports that could drive the direction of interest ratesCurrency traders pass by a screen showing the Korea Composite Stock Price Index (KOSPI), top center left, and the foreign exchange rate between U.S. dollar and South Korean won, top center, at the foreign exchange dealing room of the Hana Bank headquarters, in Seoul, South Korea, Friday, Dec. 5, 2025. (AP Photo/Ahn Young-joon)BANGKOK -- Shares t ...

Morgan Stanley sets a price target of $53 for FCX, indicating an 11.47% potential upside.The Rosen Law Firm announces a class action lawsuit for investors who purchased FCX securities between February 15, 2022, and September 24, 2025.FCX's current stock price is $47.55, with a year's trading range between $49.12 and $27.66.Freeport-McMoRan Inc. (NYSE: FCX) is a leading mining company known for its significant copper, gold, and molybdenum reserves. As a major player in the mining industry, FCX competes with ...

Investor Michael Burry has doubled down on his claims regarding GPU depreciation at leading hyperscalers and AI companies, citing recent remarks by Microsoft Corp. (NASDAQ:MSFT) CEO Satya Nadella, who highlighted the complex economics of large-scale data center investments. Burry Regrets Not Being More Vocal In 2008On Monday, in a post on X, Burry, who rose to prominence for shorting the housing market ahead of the 2008 financial crisis, said that he regrets not warning others more effectively about the ris ...

Core Viewpoint - A coalition of 20 app developers and consumer groups is urging European regulators to enforce EU laws against Apple, claiming that the company's fee structure creates an unfair disadvantage for European developers compared to their U.S. counterparts following a recent U.S. court decision [1] Group 1 - The coalition consists of 20 app developers and consumer groups [1] - The call to action is directed towards European regulators to take measures against Apple [1] - The complaint centers around Apple's fee structure, which is perceived as unfair to European developers [1] Group 2 - The issue arises in the context of a recent court decision in the United States that may impact the competitive landscape [1] - The coalition argues that the disparity in fees affects the ability of European developers to compete effectively with U.S. rivals [1]

Core Viewpoint - Bloomin' Brands (BLMN) is likely to cut its dividend due to financial constraints, as it cannot afford to pay the dividend and is utilizing cash from selling its restaurants [1] Group 1: Financial Performance - The company has been facing challenges that have led to the decision to potentially reduce its dividend payments [1] Group 2: Strategic Moves - Bloomin' Brands is selling its restaurants to generate cash, indicating a strategic shift to manage its financial obligations [1]

Jefferies downgrades NASDAQ:ADP from Hold to Underperform despite recent innovations.ADP integrates with Thatch ICHRA platform, aiming to benefit over 900,000 small businesses.The stock experiences a slight decrease, reflecting market reactions to both the downgrade and the new integration.Automatic Data Processing, Inc. (NASDAQ:ADP) is a prominent provider of human resources management software and services. The company offers a range of solutions, including payroll, talent management, and benefits adminis ...

Core Viewpoint - Genflow Biosciences has successfully completed the dosing phase of its canine gene therapy trial, with no adverse events reported, indicating a strong safety profile for the investigational SIRT6-based therapy [1][2]. Group 1: Trial Progress and Safety - All dogs enrolled in the clinical trial have received the full administration of the gene therapy without any reported adverse events, demonstrating a strong safety and tolerability profile [1][2]. - The trial is a blinded study, and efficacy outcomes will be assessed in mid-to-late January 2026, which will include blood analyses and muscle biopsies to evaluate therapeutic benefits related to sarcopenia and healthspan biomarkers [3]. - The dogs will be monitored for a total duration of 180 days, with a second efficacy assessment planned at the six-month mark, expected to yield results in June-July 2026 [4]. Group 2: Future Plans and Licensing - Following the analysis of efficacy data, Genflow plans to resume discussions with various animal health companies to explore potential early-stage licensing opportunities [5]. - Dr. Eric Leire, CEO of Genflow, emphasized the significance of these milestones for the longevity program and expressed anticipation for sharing initial efficacy data in the coming months [6]. Group 3: Company Background - Genflow Biosciences, founded in 2020 and headquartered in the UK, focuses on pioneering gene therapies aimed at decelerating the aging process and promoting longer, healthier lives [7]. - The company's lead compound, GF-1002, utilizes a centenarian variant of the SIRT6 gene, which has shown promising preclinical results [7].